Incyte Corp (INCY): Paula J Swain , EVP, Human Resources of Incyte Corp sold 20,000 shares on Sep 23, 2016. The Insider selling transaction was reported by the company on Sep 26, 2016 to the Securities and Exchange Commission. The shares were sold at $90.00 per share for a total value of $1,800,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 2, 2016, Reid M Huber (EVP, Chief Scientific Officer) sold 10,000 shares at $87.96 per share price.On Aug 2, 2016, Paula J Swain (EVP, Human Resources) sold 60,000 shares at $90.00 per share price.Also, On Jan 8, 2016, Richard S Levy (EVP, Chief Drug Dev Officer) sold 3,937 shares at $101.86 per share price.On Dec 14, 2015, Eric H. Siegel (EVP, General Counsel) sold 1,936 shares at $107.96 per share price.
Incyte Corporation: On Thursday, Sep 22, 2016 heightened volatility was witnessed in Incyte Corporation which led to swings in the share price. The shares opened for trading at $87.81 and hit $89.48 on the upside , eventually ending the session at $89.27, with a gain of 2.95% or 2.56 points. The heightened volatility saw the trading volume jump to 14,40,995 shares. The 52-week high of the share price is $131.33 and the company has a market cap of $16,783 M . The 52-week low of the share price is at $55.
Company has been under the radar of several Street Analysts.Incyte Corporation is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 100 from a previous price target of $85 .The Rating was issued on Aug 10, 2016.Incyte Corporation is Reiterated by Leerink Partners to Outperform and the brokerage firm has raised the Price Target to $ 95 from a previous price target of $85 .The Rating was issued on Aug 10, 2016.Incyte Corporation is Initiated by SunTrust to Buy. The Rating was issued on Aug 5, 2016.Incyte Corporation is Initiated by RBC Capital Mkts to Outperform and the brokerage firm has set the Price Target at $105. The Rating was issued on Jul 13, 2016.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company’s compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received development and commercialization rights f